Log in / Register

Empowering healthcare professionals through leading medical research

Courses
About
Contact

Questions – Real-world studies in migraine

Access

Register your details to create a user profile, then log in to access the courses.

Register

Already registered? Click to log in.

Real-world studies in migraine
Questions – Real-world studies in migraine

Please select the appropriate response for the questions below. Select “View Questions” upon completion to view question feedback.

Time limit: 0

Quiz Summary

0 of 30 Questions completed

Questions:

Information

You have already completed the quiz before. Hence you can not start it again.

Quiz is loading…

You must sign in or sign up to start the quiz.

You must first complete the following:

Results

Quiz complete. Results are being recorded.

Results

0 of 30 Questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Average score
Your score

Categories

Not categorized 0%

Review
Answered
Correct
Incorrect

Question 1 of 30

1. Question

In the article by Demirsoy, compared to individuals without diagnosed migraine, those with migraine in the “All of Us” Research Program were found to have significantly higher rates of which of the following?

Reference: https://doi.org/10.1111/head.15007

A. Having Medicare as primary insurance
Correct Incorrect Correct answer

B. Reporting the same healthcare coverage compared to last year
Correct Incorrect Correct answer

C. Seeking care from a doctor's office only once over the past year
Correct Incorrect Correct answer

D. Skipping medication doses to save money
Correct Incorrect Correct answer

E. Using emergency or urgent care services
Correct Incorrect Correct answer

Correct

Incorrect
Question 2 of 30

2. Question

In the article by Demirsoy, which social factor was associated with lower odds of encountering financial and access barriers to healthcare utilization for those with migraine?

Reference: https://doi.org/10.1111/head.15007

A. Being a student
Correct Incorrect Correct answer

B. Being unable to work
Correct Incorrect Correct answer

C. Being married
Correct Incorrect Correct answer

D. Being self-employed
Correct Incorrect Correct answer

E. Being a homemaker
Correct Incorrect Correct answer

Correct

Incorrect
Question 3 of 30

3. Question

In the article by Demirsoy, which type of barrier to health care utilization showed the highest adjusted odds ratio for individuals unable to work compared to those with salary support?

Reference: https://doi.org/10.1111/head.15007

A. Access
Correct Incorrect Correct answer

B. Attitudinal
Correct Incorrect Correct answer

C. Comorbidity
Correct Incorrect Correct answer

D. Financial
Correct Incorrect Correct answer

E. Social
Correct Incorrect Correct answer

Correct

Incorrect
Question 4 of 30

4. Question

In the article by Nikitina, which of the following is the most frequently reported type of adverse drug reactions for the migraine prophylactic monoclonal antibodies?

Reference: https://doi.org/10.1111/head.14962

A. Cardiovascular events
Correct Incorrect Correct answer

B. Gastrointestinal issues
Correct Incorrect Correct answer

C. Injection site reactions
Correct Incorrect Correct answer

D. Serious infections
Correct Incorrect Correct answer

E. Visual disturbances
Correct Incorrect Correct answer

Correct

Incorrect
Question 5 of 30

5. Question

In the article by Nikitina, which statement best reflects the study’s conclusion regarding the safety of migraine prophylactic monoclonal antibodies (mAbs) after analysis of the EudraVigilance database?

Reference: https://doi.org/10.1111/head.14962

A. The mAbs exhibited significant safety concerns warranting immediate restrictions in their use.
Correct Incorrect Correct answer

B. The mAbs have a higher risk of cardiovascular adverse events compared to topiramate.
Correct Incorrect Correct answer

C. The mAbs are associated with a higher reporting frequency of serious adverse events.
Correct Incorrect Correct answer

D. The most reported ADRs were nonserious and consistent with existing literature, emphasizing the need for ongoing safety monitoring.
Correct Incorrect Correct answer

E. The mAbs exhibited a lower reporting frequency of adverse events compared to topiramate, suggesting a superior safety profile.
Correct Incorrect Correct answer

Correct

Incorrect
Question 6 of 30

6. Question

In the article by Nikitina, the disproportionality analysis comparing migraine prophylactic monoclonal antibodies to topiramate revealed the highest significant disproportionality signals for which of the following?

Reference: https://doi.org/10.1111/head.14962

A. Both fremanezumab and erenumab
Correct Incorrect Correct answer

B. Eptinezumab
Correct Incorrect Correct answer

C. Erenumab
Correct Incorrect Correct answer

D. Fremanezumab
Correct Incorrect Correct answer

E. Galcanezumab
Correct Incorrect Correct answer

Correct

Incorrect
Question 7 of 30

7. Question

In the article by Rosen, what primary outcome related to opioid use significantly decreased after rimegepant initiation in individuals with migraine?

Reference: https://doi.org/10.1111/head.15004

A. The average dispensed morphine milligram equivalents
Correct Incorrect Correct answer

B. The average duration of use for statins
Correct Incorrect Correct answer

C. The number of days supplied for rescue inhalers
Correct Incorrect Correct answer

D. The proportion of individuals using buprenorphine
Correct Incorrect Correct answer

E. The total number of prescriptions for codeine
Correct Incorrect Correct answer

Correct

Incorrect
Question 8 of 30

8. Question

In the article by Rosen, what was the definition of “problematic opioid use” in the subgroup analysis?

Reference: https://doi.org/10.1111/head.15004

A. ≥ 10 opioid prescriptions during the pre-index period
Correct Incorrect Correct answer

B. ≥ 3 opioid prescriptions and/or morphine milligram equivalents (MME) in the fourth quartile during the pre-index period
Correct Incorrect Correct answer

C. Daily opioid use for longer than 3 months
Correct Incorrect Correct answer

D. Use of any opioid medication for more than 6 months
Correct Incorrect Correct answer

E. History of opioid dependence
Correct Incorrect Correct answer

Correct

Incorrect
Question 9 of 30

9. Question

In the article by Rosen, what percentage of butalbital users discontinued opioids after starting rimegepant?

Reference: https://doi.org/10.1111/head.15004

A. 19.50%
Correct Incorrect Correct answer

B. 36.00%
Correct Incorrect Correct answer

C. 38.40%
Correct Incorrect Correct answer

D. 48.30%
Correct Incorrect Correct answer

E. 56.90%
Correct Incorrect Correct answer

Correct

Incorrect
Question 10 of 30

10. Question

In the article by Sebrow, which of the following cognitive functioning tasks were not found to be statistically significant?

Reference: https://doi.org/10.1111/head.14964

A. Trail making tests
Correct Incorrect Correct answer

B. Spatial memory
Correct Incorrect Correct answer

C. Stroop (correct non-congruent)
Correct Incorrect Correct answer

E. Stroop (incorrect non-congruent)
Correct Incorrect Correct answer

Correct

Incorrect
Question 11 of 30

11. Question

In the article by Sebrow, which of the following do people with migraine rank as the most disabling symptoms of migraine?

Reference: https://doi.org/10.1111/head.14964

A. Photophobia
Correct Incorrect Correct answer

B. Phonophobia
Correct Incorrect Correct answer

C. Dizziness
Correct Incorrect Correct answer

D. Cognitive symptoms
Correct Incorrect Correct answer

E. Nausea
Correct Incorrect Correct answer

Correct

Incorrect
Question 12 of 30

12. Question

In the article by Sebrow, how many times per day were people asked to complete assessments?

Reference: https://doi.org/10.1111/head.14964

A. Three
Correct Incorrect Correct answer

B. Four
Correct Incorrect Correct answer

C. Five
Correct Incorrect Correct answer

D. Six
Correct Incorrect Correct answer

E. Nightly
Correct Incorrect Correct answer

Correct

Incorrect
Question 13 of 30

13. Question

In the article by Terwindt, what percentage of patients with menstrually related migraine were “extremely satisfied” with acute treatment?

Reference: https://doi.org/10.1111/head.14996

A. 10%
Correct Incorrect Correct answer

B. 16%
Correct Incorrect Correct answer

C. 18%
Correct Incorrect Correct answer

D. 19%
Correct Incorrect Correct answer

E. 23%
Correct Incorrect Correct answer

Correct

Incorrect
Question 14 of 30

14. Question

In the article by Terwindt, which of the following is the most likely prescription those with menstrual migraine reported receiving?

Reference: https://doi.org/10.1111/head.14996

A. NSAID's
Correct Incorrect Correct answer

B. Opioid analgesics
Correct Incorrect Correct answer

C. Triptans
Correct Incorrect Correct answer

D. Anti-CGRP gepant
Correct Incorrect Correct answer

E. Sertonin 5-HT1F Aognist (Ditan)
Correct Incorrect Correct answer

Correct

Incorrect
Question 15 of 30

15. Question

In the article by Terwindt, which of the following is incorrect regarding the demographics of included patients with menstrual migraine?

Reference: https://doi.org/10.1111/head.14996

A. younger age
Correct Incorrect Correct answer

B. higher BMI
Correct Incorrect Correct answer

C. lower BMI
Correct Incorrect Correct answer

D. currently a student
Correct Incorrect Correct answer

E. white
Correct Incorrect Correct answer

Correct

Incorrect
Question 16 of 30

16. Question

Which outcomes were measured in the study by de Dios et al?

Reference: https://doi.org/10.1111/head.14827

A. Treatment persistence, defined as the number of days between the start and end dates of treatment or the end of follow-up
Correct Incorrect Correct answer

B. Treatment persistence, decribed as the percentage of patients remaining on treatment at 3, 6, and 12 months
Correct Incorrect Correct answer

C. Effectiveness, defined as a ≥ 50 % reduction in monthly migraine days
Correct Incorrect Correct answer

D. Tolerability, assessed by the number and type of adverse events
Correct Incorrect Correct answer

E. All of the above
Correct Incorrect Correct answer

Correct

Incorrect
Question 17 of 30

17. Question

According to the article by de Dios et al., which of the following statements is supported?

Reference: https://doi.org/10.1111/head.14827

A. There is a lower persistence rate for the first anti-CGRP mAb treatment compared to subsequent switches
Correct Incorrect Correct answer

B. Switching is never recommended, because the second and third CGRP mAbs showed inferior results in all outcomes.
Correct Incorrect Correct answer

C. Erenumab showed higher persistence, although the difference was not statistically significant.
Correct Incorrect Correct answer

D. During the study period, no events occurred that could have affected the follow-up process.
Correct Incorrect Correct answer

E. Fewer than 10 % of patients reported adverse events, which never led to treatment discontinuation, confirming the favorable safety profile of CGRP mAbs.
Correct Incorrect Correct answer

Correct

Incorrect
Question 18 of 30

18. Question

In this article by Dios, which of the following challenges in regards to the prescription and use of CGRP monoclonal antibodies is not described?

Reference: https://doi.org/10.1111/head.14827

A. Maintaining efficacy
Correct Incorrect Correct answer

B. Anti-drug antibody development
Correct Incorrect Correct answer

C. Maintatining tolerability
Correct Incorrect Correct answer

D. Difficult with administration
Correct Incorrect Correct answer

E. Treatment Persistence
Correct Incorrect Correct answer

Correct

Incorrect
Question 19 of 30

19. Question

In this study by Jaimes et al., which of the following best describes the authors’ statements and methods?

Reference: https://doi.org/10.1111/head.14865

A. CGRP mAbs can target both CGRP and CGRP receptors.
Correct Incorrect Correct answer

B. The efficacy, safety, and tolerability of both the initial use and switching among CGRP mAbs have been established through clinical trials and real-world studies.
Correct Incorrect Correct answer

C. Switching between CGRP mAbs in real-world settings occurs due to ineffectiveness, loss of effectiveness upon reinitiation, adverse effects, and administrative reasons.
Correct Incorrect Correct answer

D. The decision regarding which CGRP mAb to switch to was made by the patients.
Correct Incorrect Correct answer

E. A priori statistical power calculation was not conducted, and sample size was determined by available data.
Correct Incorrect Correct answer

Correct

Incorrect
Question 20 of 30

20. Question

Which of the following best describes the findings reported in the article by Jaimes et al.?

Reference: https://doi.org/10.1111/head.14865

A. The modal number of doses of the first mAb was eight.
Correct Incorrect Correct answer

B. The most common reason for switching was ineffectiveness, and the least common was loss of effectiveness upon reinitiation.
Correct Incorrect Correct answer

C. Most patients had inter-treatment intervals of more than two months.
Correct Incorrect Correct answer

D. The authors reported a statistically significant decrease in HIT-6 scores at three months after switching.
Correct Incorrect Correct answer

E. The first types of CGRP mAbs were evenly distributed among erenumab, galcanezumab, and fremanezumab.
Correct Incorrect Correct answer

Correct

Incorrect
Question 21 of 30

21. Question

Based on the logistic regression analysis by Jaimes et al., which of the following factors was associated with a ≥50% reduction in MHDs at three months after switching?

Reference: https://doi.org/10.1111/head.14865

A. The number of doses of the first mAb
Correct Incorrect Correct answer

B. The inter-treatment interval
Correct Incorrect Correct answer

C. Number of previous preventive treatments
Correct Incorrect Correct answer

D. Sex
Correct Incorrect Correct answer

None of the above
Correct Incorrect Correct answer

Correct

Incorrect
Question 22 of 30

22. Question

In the study by Joshi et al. (2024), what was the percentage of patients using multiple preventive medications over the 3 year follow-up?

Reference: https://doi.org/10.1111/head.14741

A. 71.1%
Correct Incorrect Correct answer

B. 61.1%
Correct Incorrect Correct answer

C. 91.1%
Correct Incorrect Correct answer

D. 81.1%
Correct Incorrect Correct answer

E. 51.1%
Correct Incorrect Correct answer

Correct

Incorrect
Question 23 of 30

23. Question

In the article by Joshi et al. (2024), which of the following was NOT true of the preventive migraine treatment (PMT) cohort?

Reference: https://doi.org/10.1111/head.14741

A. Almost 20% of patients stayed on the same migraine preventive treatment at the end of the 3-year follow-up.
Correct Incorrect Correct answer

B. Patients with gaps (>30 days) between switches to different preventive treatments comprised the largest subgroup in the study.
Correct Incorrect Correct answer

C. Patients who switched to other therapies without any gaps reported the highest medication overuse.
Correct Incorrect Correct answer

D. Patients who switched to other therapies without any gaps reported the highest direct costs in each year of the study.
Correct Incorrect Correct answer

E. The risk of having a treatment gap was 20% higher in the second line of treatment compared to the firstline of treatment.
Correct Incorrect Correct answer

Correct

Incorrect
Question 24 of 30

24. Question

According to the study by Joshi et al. (2024), which factor was related to a higher risk of treatment gap in both the first and second lines of treatment?

Reference: https://doi.org/10.1111/head.14741

A. Younger age
Correct Incorrect Correct answer

B. Male sex
Correct Incorrect Correct answer

C. Female sex
Correct Incorrect Correct answer

D. Presence of comorbidities
Correct Incorrect Correct answer

E. Longer follow-up time
Correct Incorrect Correct answer

Correct

Incorrect
Question 25 of 30

25. Question

In the article by Moskatel, which of the following CGRP monoclonal antibodies was found to be prescribed the most between 2018 and 2021 in this population?

Reference: https://doi.org/10.1111/head.14642

A. Erenumab
Correct Incorrect Correct answer

B. Galcanezumab
Correct Incorrect Correct answer

C. Fremanezumab
Correct Incorrect Correct answer

D. Eptinezumab
Correct Incorrect Correct answer

Correct

Incorrect
Question 26 of 30

26. Question

In the article by Moskatel, which of the following medications did not have a signficant change in prescriptions?

Reference: https://doi.org/10.1111/head.14642

A. Amitriptyline
Correct Incorrect Correct answer

B. Memantine
Correct Incorrect Correct answer

C. Propranolol
Correct Incorrect Correct answer

D. Venlafaxine
Correct Incorrect Correct answer

E. Verapamil
Correct Incorrect Correct answer

Correct

Incorrect
Question 27 of 30

27. Question

In the article by Moskatel, which of the following is not described as a benefit to CGRP mAbs compared to oral preventives?

Reference: https://doi.org/10.1111/head.14642

A. More tolerable side effects
Correct Incorrect Correct answer

B. Superior efficacy
Correct Incorrect Correct answer

C. Improved adherence
Correct Incorrect Correct answer

D. Reduced dosing
Correct Incorrect Correct answer

Correct

Incorrect
Question 28 of 30

28. Question

In the article by Robblee, what percentage of respondents chose to treat an attack like Status migrainosus (SM) when the patient did not repond to their usual home treatment, even if less than 3 days?

Reference: https://doi.org/10.1111/head.14769

A. 55%
Correct Incorrect Correct answer

B. 61%
Correct Incorrect Correct answer

C. 69%
Correct Incorrect Correct answer

D. 72%
Correct Incorrect Correct answer

E. 80%
Correct Incorrect Correct answer

Correct

Incorrect
Question 29 of 30

29. Question

In the article by Robblee, which of the following responses was chosen most often when asked about the first step in treating Status migrainosus (SM)?

Reference: https://doi.org/10.1111/head.14769

A. Outpatient medications
Correct Incorrect Correct answer

B. In clinic procedure
Correct Incorrect Correct answer

C. IV medications
Correct Incorrect Correct answer

D. ER/Urgent Care
Correct Incorrect Correct answer

E. Direct admission
Correct Incorrect Correct answer

Correct

Incorrect
Question 30 of 30

30. Question

In the article by Robblee, which of the following medication categories were used most often as a medication to use at home as Status migrainosus (SM) treatment?

Reference: https://doi.org/10.1111/head.14769

A. Triptans
Correct Incorrect Correct answer

B. Neuroleptics
Correct Incorrect Correct answer

C. Antiseizure
Correct Incorrect Correct answer

D. Corticosteroids
Correct Incorrect Correct answer

E. Muscle relaxants
Correct Incorrect Correct answer

Correct

Incorrect

Share

Courses by Journal

Alimentary Pharmacology and Therapeutics
American Family Physician
American Journal of Hematology
American Journal on Addictions
Diabetes Obesity and Metabolism
Headache
International Journal of Dermatology
Journal of Cosmetic Dermatology
Journal of the International AIDS Society
Pediatric Dermatology
Transfusion
Transfusion News

Courses by Specialty

Addiction
Dermatology
Emergency Medicine
Gastroenterology & Hepatology
Hematology
Immunology
Neurology
Pharmacology
Primary Care
Psychiatry

© Copyright 2025 John Wiley & Sons, Inc., or related companies. All rights reserved.

About
Privacy
Terms of Use
Contact Us
Cookie Preferences

Login

Accessing this course requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?

Register

Don't have an account? Register one!

Register an Account